Compare Stocks

Esprit Holdings Limited, an investment holding company, engages in the retail and wholesale distribution, and licensing of fashion and non-apparel products. The company offers apparels, accessories, lifestyle, and other products for women, men, and kids under the Esprit and edc brand names through retail stores and e-commerce platforms. It also engages in the Sourcing, purchasing, distributing, and sale of merchandise; provision of logistic services; design and image directions; and conceptualization and development of global uniform image businesses. Esprit Holdings Limited was founded in 1968 and is headquartered in North Point, Hong Kong.

Nextech3D.AI Corporation provides augmented reality technologies, wayfinding technologies, and 3D model services. It focuses on creating 3D WebAR photorealistic models for the prime ecommerce marketplace, as well as other online retailers. The company was formerly known as NexTech AR Solutions Corp. and changed its name to Nextech3D.AI Corporation in September 2023. Nextech3D.AI Corporation was incorporated in 2018 and is headquartered in Toronto, Canada.

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

The Taiwan Fund, Inc. is a closed-ended equity mutual fund launched and managed by Nomura Asset Management U.S.A. Inc. It invests in the public equity markets of Taiwan. The fund seeks to invest in stocks of companies operating across diversified sectors. It employs fundamental analysis focusing on such factors as overall growth prospects, competitive position in the respective industry, technology, research, and development, productivity, labor costs, raw material costs and sources, profit margins, return on investment, capital resources, government regulation, and management to create its portfolio. The fund benchmarks the performance of its portfolio against the TAIEX Total Return Index. The Taiwan Fund, Inc. was formed on December 23, 1986 and is domiciled in the United States.